Gsk (GSK) Net Income towards Common Stockholders (2009 - 2026)

Gsk (GSK) has 18 years of Net Income towards Common Stockholders data on file, last reported at $2.9 billion in Q3 2026.

• For the quarter ending Q3 2026, Net Income towards Common Stockholders changed N/A year-over-year to $2.9 billion; the trailing twelve-month figure through Sep 2026 stood at $9.9 billion (changed N/A YoY), and the FY2025 full-year result was $7.6 billion, up 130.99% from the prior year.
• Net Income towards Common Stockholders was $2.9 billion for Q3 2026 at Gsk, up from $583.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $12.8 billion in Q3 2022 to a low of -$75.4 million in Q3 2024.
• A 5-year average of $2.7 billion and a median of $2.0 billion in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 104.06% in 2024 and soared 3704.42% in 2025, its largest moves.
• Gsk's Net Income towards Common Stockholders stood at $3.1 billion in 2022, then advanced by 24.82% to $3.9 billion in 2023, then declined by 26.31% to $2.8 billion in 2024, then jumped by 43.24% to $4.1 billion in 2025, then slipped by 28.52% to $2.9 billion in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $2.9 billion in Q3 2026, $583.6 million in Q2 2026, and $2.3 billion in Q1 2026.